VIRALEZE™ launch in ADMENTA Italia Group pharmacies in Italy (ASX Announcement)

Oct 8th, 2021

Starpharma today announced it has signed a sales and distribution agreement for VIRALEZE™ antiviral nasal spray with ADMENTA Italia Group (ADMENTA), a leading pharmaceutical retail and wholesale distribution company in Italy. 

2021 Annual General Meeting (ASX Announcement)

Oct 1st, 2021

Starpharma today notifies that the AGM of Starpharma Holdings Limited will be held as a virtual event at 11:00am (Melbourne time) on Tuesday, 30 November 2021.

US patent issued for DEP® cabazitaxel nanoparticle (ASX Announcement)

Sep 15th, 2021

Starpharma today announced that the US Patent and Trademark Office has granted a new patent in relation to DEP^® cabazitaxel.

Starpharma annual report and full year financial results (ASX Announcement)

Aug 26th, 2021

Starpharma today released its annual report and financial results for the year ended 30 June 2021.

VIRALEZE™ Protects Against SARS-CoV-2 in Challenge Model (ASX Announcement)

Aug 23rd, 2021

Starpharma today announced publication of new data demonstrating the protective efficacy of VIRALEZE™ antiviral nasal spray against SARS-CoV-2 challenge in vivo in a humanised mouse model of coronavirus infection. The results of the study have been published in the international peer-reviewed journal, Viruses, in a special issue titled, Medical Interventions for Treatment and Prevention of SARS-CoV-2 Infections (https://www.mdpi.com/1999-4915/13/8/1656).

VIRALEZE™ well tolerated in multiple dose clinical study (ASX Announcement)

Aug 17th, 2021

Starpharma today announced results from its VIRALEZE™ clinical safety study demonstrating the product was safe and well tolerated in accordance with the primary endpoint, and also confirming that the dendrimer antiviral in VIRALEZE™, SPL7013, was not absorbed into the bloodstream following nasal application.  

Quarterly Cashflow and Activities Report (ASX Announcement)

Jul 30th, 2021

Starpharma (ASX: SPL, OTCQX: SPHRY) today released its Appendix 4C – Quarterly Cashflow Report for the period ended 30 June 2021.

Lynda Cheng appointed as non-executive director (ASX Announcement)

Jul 28th, 2021

Starpharma to present DEP® platform at CRS Annual Meeting (ASX Announcement)

Jul 27th, 2021

Starpharma (ASX:SPL) shows 99.99pc antiviral activity against Delta COVID-19 variant

Jul 27th, 2021

VIRALEZE SPL7013 virucidal (>99.99%) against Delta variant (ASX Announcement)

Jul 27th, 2021

Starpharma today announced new data demonstrating that SPL7013, the antiviral agent in VIRALEZE™ nasal spray, is active against the highly transmissible Delta variant of SARS-CoV-2, achieving more than 99.99% reduction of infectious virus in laboratory-based virucidal assays.

TGA infringement notices for alleged advertising (ASX Announcement)

Jul 5th, 2021

Starpharma today announces it has received several infringement notices from the TGA with respect to alleged advertising of VIRALEZE™ antiviral nasal spray to Australian consumers.

Starpharma to present at Virtual Life Sciences Investor Forum (ASX Announcement)

Jun 24th, 2021

Starpharma today announced that a presentation by Dr Jackie Fairley, CEO, will be broadcast on Thursday 24 June 2021 (US ET) as part of OTCQX’s Virtual Life Sciences Investor Forum. The Life Sciences Investor Forum is a leading investor conference that is attended by tens of thousands of investors, primarily US-based retail investors, as well as advisors.

VIRALEZE UK update (ASX Announcement)

Jun 21st, 2021

Starpharma advises that its UK retail partner, LloydsPharmacy, has received correspondence from the UK Medicines and Healthcare products Regulatory Agency (MHRA) in relation to specific promotional claims made for VIRALEZE™ antiviral nasal spray.

VIRALEZE SPL7013 virucidal against multiple COVID variants (ASX Announcement)

Jun 18th, 2021

Starpharma today released new data demonstrating that SPL7013, the active in VIRALEZE^™ antiviral nasal spray, achieved more than 99.9% reduction of virus against the Alpha (UK), Beta (South Africa) and Gamma (Japan/Brazil) SARS-CoV-2 coronavirus ‘Variants of Concern’ in laboratory-based virucidal assays.

VIRALEZE antiviral nasal spray registered for sale in India (ASX Announcement)

Jun 11th, 2021

Starpharma today announced it had received confirmation that VIRALEZE^™ antiviral nasal spray has been registered for sale nationally in India via the Central Drugs Standard Control Organisation (CDSCO), which is part of the Indian Ministry of Health and Family Welfare.

VIRALEZE SPL7013 highly active in UK variant of coronavirus (ASX Announcement)

Jun 1st, 2021

Starpharma today announced new data confirming that SPL7013, the active in VIRALEZE^™ antiviral nasal spray, has potent antiviral activity against the UK (B.1.1.7) SARS-CoV-2 variant of concern (hCoV-19/England/204820464/2020) in laboratory studies, achieving more than 98% reduction in infectious virus in antiviral assays.

VIRALEZE™ partners with Harlequins in the UK (ASX Announcement)

May 11th, 2021

Starpharma attaches a media release announcing the partnership between VIRALEZE™ and Harlequins in the UK, which was distributed today. (Click here)

Harlequins is a professional English rugby union team, established in 1866, and one of the founding members of the Rugby Football Union. Harlequins play in the English Premiership, the top level of English rugby union. The Club’s home ground is the Twickenham Stoop Stadium, “The Stoop”, in south-west London. For more information about Harlequins, visit www.quins.co.uk.

VIRALEZE™ launches in Europe (ASX Announcement)

May 6th, 2021

Starpharma today announced that VIRALEZE^™ antiviral nasal spray is now available for purchase by consumers in Europe via Starpharma’s www.viraleze.co webstore.

Shareholder Update April 2021

Apr 28th, 2021

The Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) Shareholder Update – April 2021 is now available to view online.

Quarterly Cashflow and Activities Report

Apr 27th, 2021

Starpharma (ASX: SPL, OTCQX: SPHRY) today released its Appendix 4C – Quarterly Cashflow Report for the period ended 31 March 2021.

VIRALEZE™ now launched by LloydsPharmacy in the UK

Mar 30th, 2021

Starpharma today confirms that Starpharma’s VIRALEZE™ antiviral nasal spray has launched in the UK by LloydsPharmacy, as announced on 25 March 2021.

VIRALEZE™ to be launched with LloydsPharmacy in the UK

Mar 25th, 2021

Starpharma today announced it has signed a sales and distribution agreement for VIRALEZE™ antiviral nasal spray with LloydsPharmacy and the McKesson group in the UK. LloydsPharmacy/McKesson is one of the largest pharmacy groups in the UK and is also a major wholesaler in the UK.

DEP® HER2-lutetium outperforms in human breast cancer model

Mar 16th, 2021

Starpharma today announced that its second radiopharmaceutical candidate, DEP^® HER2-lutetium, achieved potent and durable anticancer activity, with complete tumour regression, outperforming Herceptin^® (trastuzumab) labelled with lutetium, in a human breast cancer model (BT474).

SPL7013 active against other pandemic coronaviruses

Mar 3rd, 2021

Starpharma today announces new data from The Scripps Research Institute in the US and other specialist laboratories on the activity of SPL7013 against important respiratory viruses, including those responsible for past pandemics. This new data further confirms the broad spectrum antiviral properties of SPL7013 (VIRALEZE™ active), with SPL7013 blocking the spike protein of two additional important pandemic causing coronaviruses, SARS-CoV and MERS‑CoV.

Interim Report and Half-Year Financial Results

Feb 25th, 2021

Starpharma today released its interim report and financial results for the half-year ended 31 December 2020.

VIRALEZE™ antiviral nasal spray registered in Europe

Feb 23rd, 2021

Starpharma announced today it had received confirmation that the VIRALEZE™ antiviral nasal spray has been successfully registered for sale in Europe, including in the UK.

Starpharma signs DEP® ADC Research Agreement with MSD

Feb 12th, 2021

Starpharma today announced that is has signed a Research Agreement with MSD, the tradename of Merck & Co., Inc., Kenilworth NJ USA. Under the agreement, MSD will conduct a preclinical research evaluation of dendrimer based Antibody Drug Conjugates (ADCs) utilising Starpharma’s proprietary DEP^® technology.

AZD0466 clinical DEP® program global expansion

Feb 9th, 2021

Starpharma today announced that it had been advised by AstraZeneca of its intention to expand the clinical program for AZD0466 to include a multi-centre global Phase 1 study. The study will recruit patients with acute leukaemias.

Quarterly Cashflow and Activity Report

Jan 29th, 2021

Starpharma released its Appendix 4C – Quarterly Cashflow Report for the period ended 31 December 2020.

VIRALEZE COVID-19 nasal spray study to commence in January

Dec 22nd, 2020

Starpharma today announced that it has received all necessary approvals to commence its clinical study for VIRALEZE™. The study will commence enrolment of healthy volunteers in Perth in early January 2021 and is expected to be completed in Q1 2021. This study is being undertaken to support commercialisation activities for VIRALEZE™, and is not a requirement to achieve EU product registration.  

VIRALEZE™ COVID-19 nasal spray to be ready for market Q1CY21

Dec 10th, 2020

Starpharma today announced significant commercial and regulatory progress has been made for VIRALEZE™ nasal spray with the EU regulatory dossier more than 90% complete and VIRALEZE™ now on track to be registered, and ready for market in Q1 CY2021. This timing is earlier than previously announced.

AGM Chairman address and CEO presentation

Nov 20th, 2020

Attached is the Chairman’s address together with the CEO’s presentation to the Annual General Meeting (AGM) of Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY), to be held at 11am (Melbourne time) today.

SPL7013 shows potent antiviral activity in RSV expanding use for nasal spray

Nov 19th, 2020

Starpharma today announced it has completed additional testing showing potent antiviral activity of SPL7013 against human respiratory syncytial virus (RSV). RSV is a common and very contagious virus that affects the lungs and airways. RSV is most problematic in the young and the elderly and those with weakened immune systems, or chronic heart and lung disease, including asthma. More than 177,000 adults are hospitalized and 14,000 of them die due to RSV infection in the US annually. RSV is also one of the viruses responsible for the common cold.

Quarterly Cashflow and Activities Report

Oct 30th, 2020

Starpharma today released its Appendix 4C – Quarterly Cashflow Report for the period ended 30 September 2020.

Completion of Placement and SPP raises $48.9M in total

Oct 29th, 2020

Starpharma today announced that it has completed its Share Purchase Plan (SPP), raising $3.9 million. The SPP was conducted in conjunction with Starpharma’s recent institutional placement (Placement), which together have raised a total of $48.9 million. The issue of 2.6 million new shares under the SPP will be at $1.50 per share, being equivalent to the Placement share price.

Starpharma receives $5.7M R&D tax incentive refund

Oct 21st, 2020

Starpharma today announced that it has received a $5.7M R&D tax incentive refund which relates to the costs of research and development during the 2020 Financial Year. The refund is in respect of eligible R&D activities across Starpharma’s portfolio, including for COVID-19, DEP^® and VivaGel^® programs.

Shareholder Update October 2020

Oct 20th, 2020

In this issue:

>> Starpharma is expediting the development of the SPL7013 COVID‑19 nasal spray

>> Rapid progress in the DEP^® irinotecan phase 2 & preparations underway for clinical combinations

>> DEP^® irinotecan in combination with immuno-oncology showed superior performance in colon cancer models

>> VivaGel^® BV launched in Central & Eastern Europe and Nordic region

>> Fleurstat BVgel gains expanded TGA approval to include prevention of recurrent Bacterial Vaginosis (BV) indication

>> VivaGel^® BV has now been approved in 40 countries with further submissions underway

>> Starpharma awarded $1 million MRFF funding for COVID-19 nasal spray

>> DEP^® docetaxel update & patient case study

>> DEP^® cabazitaxel update & patient case study

>> Multiple DEP^® products showcased at AACR 2020 Annual Meeting

>> New DEP^® partnership signed with Chase Sun for anti-infective program

>> AstraZeneca’s AZD0466 trial opens at MD Anderson Cancer Center

>> Starpharma creates slow release soluble DEP^® remdesivir

>> DEP^® partnering, including Antibody Drug Conjugates

>> DEP^® lutetium; impressive efficacy in human prostate cancer model

>> Outlook, Annual Report & ESG Report & recent news 

Share Purchase Plan offer document

Oct 7th, 2020

Starpharma provides the offer document for the Company's 2020 Share Purchase Plan (SPP).

Starpharma completes oversubscribed A$45M placement - SPP to follow

Sep 30th, 2020

Starpharma today announced that it has raised A$45 million via a placement to domestic and international institutional, sophisticated and professional investors (“Placement”). Eligible shareholders will also have the opportunity to participate, at the same price, through a Share Purchase Plan (SPP) which is expected to raise approximately A$5 million.

Investor Presentation

Sep 30th, 2020

Starpharma today provided its latest investor presentation.

VivaGel® BV secures TGA approval for prevention of BV

Sep 25th, 2020

Starpharma today announced that the Australia Therapeutic Goods Administration (TGA) has approved an expansion of the marketing authorisation for VivaGel^® BV (Fleurstat BVgel) to now include the indication of prevention of recurrent bacterial vaginosis. These expanded claims bring the approved indications for VivaGel^® BV (Fleurstat BVgel) in line with those in Europe and Asia.

Starpharma to present at OTCQX Life Sciences Investor Forum

Sep 17th, 2020

Starpharma today announced that a pre-recorded presentation by Dr Jackie Fairley, CEO, will be broadcast on Thursday 17 September 2020 (US ET) as part of OTCQX’s Life Sciences Investor Forum.

SPL7013 COVID-19 nasal spray virucidal against SARS-CoV-2

Sep 14th, 2020

Starpharma today announced it has completed additional antiviral testing for SPL7013 against SARS‑CoV-2 in studies conducted in the laboratory of internationally recognised virology researcher, Professor Philippe Gallay, at the renowned Scripps Research Institute in the US.

Starpharma awarded $1M MRFF funding for COVID-19 spray

Sep 3rd, 2020

Starpharma today announced the award of $1 million in matched funding by the Australian Government’s Medical Research Future Fund (MRFF) Biomedical Translation Bridge (BTB) Program to expedite development and commercialisation of its COVID‑19 antiviral nasal spray based on Starpharma’s proprietary dendrimer, SPL7013.

SPL creates slow release soluble DEP® remdesivir nanoparticle

Sep 1st, 2020

Starpharma today announced it has applied its novel DEP^® drug delivery technology to create a long‑acting, water soluble version of remdesivir. Remdesivir is an antiviral drug, currently being developed by Gilead to treat COVID-19 and has emergency use authorisation from the US Food and Drug Administration for the treatment of COVID-19 in adults and children hospitalised with severe disease.

Annual report and full year financial results

Aug 27th, 2020

Melbourne, Australia: Starpharma today released its annual report and financial results for the year ended 30 June 2020.

SPL7013 nasal spray for COVID-19 – development update

Aug 25th, 2020

Starpharma today announced progress with development, regulatory and manufacturing activities associated with a nasal spray for protection against COVID-19 based on the company’s proprietary antiviral dendrimer, SPL7013.

Starpharma signs new DEP® partnership with Chase Sun

Aug 17th, 2020

Starpharma today announced that it has signed a new research partnership with leading Chinese Pharmaceutical company Tianjin Chase Sun Pharmaceutical Co., Ltd. (stock code 300026; Chase Sun), to develop several DEP^® nanoparticle formulations for an anti-infective drug. The agreement also provides for the potential to conduct additional DEP^® programs, which can be across therapeutic areas beyond anti-infectives.

Quarterly Cashflow and Activities Report

Jul 30th, 2020

Starpharma today released its Appendix 4C – Quarterly Cashflow Report for the period ended 30 June 2020.